Two Sigma Investments
NAVB

Two Sigma Investments’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Two Sigma Investments’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,467
Closed -$33K – 4813
2021
Q4 		$33K Sell
33,467
-34,312
-51% -$48.3K ﹤0.01% 4162
2021
Q3 		$119K Sell
67,779
-35,542
-34% -$59.8K ﹤0.01% 4063
2021
Q2 		$189K Sell
103,321
-41,324
-29% -$73K ﹤0.01% 3798
2021
Q1 		$292K Buy
144,645
+42,696
+42% +$99.9K ﹤0.01% 3345
2020
Q4 		$219K Buy
101,949
+36,860
+57% +$86.9K ﹤0.01% 3071
2020
Q3 		$176K Sell
65,089
-22,261
-25% -$79.9K ﹤0.01% 2847
2020
Q2 		$344K Buy
+87,350
New +$167K ﹤0.01% 2285
2015
Q4 		– Sell
-695
Closed -$32K – 3124
2015
Q3 		$32K Buy
+695
New +$26.2K ﹤0.01% 2108

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Two Sigma Investments's NAVB Position: Q1 2022 in Review

Two Sigma Investments sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2022, closing a stake of 33,467 shares — an estimated $33K sold.

Two Sigma Investments first reported a position in NAVB in Q3 2015 and held it in 8 quarters. The position peaked at $344K in Q2 2020. 25 funds tracked by Wall St. Rank hold NAVB as of Q1 2022.

  • Two Sigma Investments reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Investments sold 33,467 Navidea Biopharmaceuticals Inc. shares in Q1 2022, an estimated $33K.
  • Two Sigma Investments first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2015 and held it in 8 quarters.
  • Two Sigma Investments's Navidea Biopharmaceuticals Inc. position peaked at $344K in Q2 2020.
  • 25 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.